CLOs on the Move

Accreditation Council for Graduate Medical Educa

www.acgme.org

 
The Accreditation Council for Graduate Medical Education (ACGME) is a private, non-profit, professional organization responsible for the accreditation of approximately 10,000 residency and fellowship programs and the approximately 800 institutions that sponsor these programs in the United States. Residency and fellowship programs educate approximately 125,000 resident and fellow physicians in 150 specialties and subspecialties. The ACGME`s mission is to improve health care and population health by assessing and advancing the quality of resident physicians` education through accreditation. We imagine a world characterized by: • A structured approach to evaluating the competency of all residents and fellows, • Motivated physician role ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.acgme.org
  • 401 North Michigan Avenue Suite 2000
    Chicago, IL USA 60611
  • Phone: 312.755.5000

Executives

Name Title Contact Details

Similar Companies

Merck Sharp and Dohme

Merck Sharp & Dohme Corp. is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vermont Gyms d/b/a Synergy Fitness

Vermont Gyms Incorporated d/b/a Synergy Fitness is a Williston, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Casa Colina Rehabilitation Hospital

Casa Colina Rehabilitation Hospital is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Pomona, CA. To find more information about Casa Colina Rehabilitation Hospital, please visit www.casacolina.org

The Evaluation Group

The Evaluation Group is a Southfield, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Assembly Biosciences

Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly`s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. We pride ourselves on creating a culture and work environment that is scientifically driven, ambitious, and collaborative. We encourage diversity of thought that leads to great innovation and are looking to add to our dynamic team great people who are driven to transform the lives of patients. We believe our Microbiome platform represents a best in class approach to developing biopharmaceutical agents from live biotherapeutic products. ABI-M201, our lead program in mildly to moderately active ulcerative colitis (UC), is currently in a phase 1b clinical trial. This program is part of a broader collaboration we established with Allergan in 2017 for gastrointestinal programs such as UC, Crohn`s disease and Irritable Bowel Syndromes with potential total development and commercial milestones of up to $2.8 billion. Our internal pipeline comprises first in class or best in class live microbial biotherapeutic approaches in areas such as oncology, immune mediated and metabolic disorders, and other areas of high medical need. Assembly is headquartered in Carmel, Indiana, while the R&D headquarters is in South San Francisco. The Company also has a microbiome manufacturing facility in Groton, CT, and offices in China.